Non-Small Cell Lung Cancer (NSCLC)

February 19th 2025

Efficacy results from cohort 1 of the phase 1b Beamion LUNG-1 trial support the decision to review zongertinib in HER2-mutant advanced NSCLC.

February 17th 2025

IBI363 demonstrated encouraging efficacy and a manageable safety profile in patients with squamous NSCLC based on results from a phase 1 trial.

February 8th 2025

Alexander Spira, MD, and Julia Lazo, RN, spoke with Melinda Reubens, who was diagnosed with EGFR-mutant NSCLC, and her husband Justin.

February 6th 2025

Radiotherapy plus camrelizumab and platinum-doublet chemotherapy showed manageable toxicity in untreated non–small cell lung cancer with brain metastases.